Cargando…

Survival of patients with stomach adenocarcinoma in North of Iran

Aim: This study was proposed for estimation of survival time in patients with stomach adenocarcinoma. Background: North of Iran has a high mortality rate of stomach adenocarcinoma. Patients and methods: The study was historical cohort. The samples were the patients with stomach adenocarcinoma referr...

Descripción completa

Detalles Bibliográficos
Autores principales: Yazdani-Charati, Jamshid, Janbabaei, Ghasem, Etemadinejad, Siavosh, Sadeghi, Samaneh, Haghighi, Firoozeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shaheed Beheshti University of Medical Sciences 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185875/
https://www.ncbi.nlm.nih.gov/pubmed/25289135
Descripción
Sumario:Aim: This study was proposed for estimation of survival time in patients with stomach adenocarcinoma. Background: North of Iran has a high mortality rate of stomach adenocarcinoma. Patients and methods: The study was historical cohort. The samples were the patients with stomach adenocarcinoma referred to Tooba Clinic between three years (2007-2010). Survival estimates were calculated using the Kaplan-Meier method the effects of covariates on survival time were assessed by, using survival parametric regression model with gamma frailty. Results: The survival probability of more than two years of patients was calculated 27.7% by using Kaplan Mayer method. The stage, metastasis, surgery, and age were the variables which affect the survival probability of patients, by using survival parametric regression model with gamma frailty and hazard ratio of patients with three treatment protocol was 0.43 times of others (P<0.01) and increasing of patients ages decrease life time of them significantly as per year increasing patient age, risk of death increased by 4% (P<0.04) and patients with staging disease lower 4 had hazard ratio lower than 0.46 times of stage 4 (P<0.01). Conclusion: The survival time of our patients is much lower than the developed countries, which are related to latency in diagnosis and therapeutic limitations.